CorMedix Stock Forecast, Price & News

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

Is CorMedix a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CorMedix stock.
View analyst ratings for CorMedix or view top-rated stocks.

What stocks does MarketBeat like better than CorMedix?

Wall Street analysts have given CorMedix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CorMedix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CorMedix's next earnings date?

CorMedix is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for CorMedix.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) released its quarterly earnings data on Thursday, August, 12th. The biotechnology company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.07 million. CorMedix had a negative trailing twelve-month return on equity of 41.62% and a negative net margin of 10,016.73%.
View CorMedix's earnings history.

How has CorMedix's stock price been impacted by COVID-19 (Coronavirus)?

CorMedix's stock was trading at $5.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRMD shares have decreased by 7.2% and is now trading at $4.66.
View which stocks have been most impacted by COVID-19.

When did CorMedix's stock split? How did CorMedix's stock split work?

CorMedix shares reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRMD?

4 analysts have issued twelve-month price targets for CorMedix's stock. Their forecasts range from $13.50 to $29.00. On average, they anticipate CorMedix's stock price to reach $21.50 in the next year. This suggests a possible upside of 361.4% from the stock's current price.
View analysts' price targets for CorMedix or view top-rated stocks among Wall Street analysts.

Who are CorMedix's key executives?

CorMedix's management team includes the following people:

• Mohammed Khoso Baluch, Chief Executive Officer & Director
• Mathew David, Chief Financial Officer & Executive Vice President
• Antony E. Pfaffle, Secretary & Chief Scientific Officer
• John L. Armstrong, EVP-Technical Operations & Head-Human Resources
• Elizabeth Masson-Hurlburt, Executive Vice President & Head-Clinical Operation

Who are some of CorMedix's key competitors?

Some companies that are related to CorMedix include Eagle Pharmaceuticals (EGRX), Mersana Therapeutics (MRSN), Emisphere Technologies (EMIS), PyroGenesis Canada (PYR), Imago BioSciences (IMGO), Rhythm Pharmaceuticals (RYTM), Silence Therapeutics (SLN), Pharming Group (PHAR), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Seres Therapeutics (MCRB), Pliant Therapeutics (PLRX), Xenon Pharmaceuticals (XENE), Adagene (ADAG) and DiaMedica Therapeutics (DMCAF).
View all of CRMD's competitors.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Trevena (TRVN), Precigen (PGEN), Advanced Micro Devices (AMD), Kindred Biosciences (KIN), OPKO Health (OPK) and Sangamo Therapeutics (SGMO).

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.55%), Vanguard Group Inc. (4.57%), Credit Suisse AG (1.97%), Geode Capital Management LLC (1.66%), State Street Corp (1.66%) and Northern Trust Corp (0.95%). Company insiders that own CorMedix stock include Alan W Dunton, Elizabeth Masson-Hurlburt, Hudson Executive Capital Lp, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz.
View institutional ownership trends for CorMedix.

Which institutional investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, Deutsche Bank AG, State Street Corp, Goldman Sachs Group Inc., Bank of America Corp DE, Bridgeway Capital Management LLC, JPMorgan Chase & Co., and Credit Suisse AG.
View insider buying and selling activity for CorMedix or view top insider-selling stocks.

Which institutional investors are buying CorMedix stock?

CRMD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Geode Capital Management LLC, State Board of Administration of Florida Retirement System, Nuveen Asset Management LLC, Qube Research & Technologies Ltd, State of Wisconsin Investment Board, and Northern Trust Corp. Company insiders that have bought CorMedix stock in the last two years include Alan W Dunton, Hudson Executive Capital Lp, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix or or view top insider-buying stocks.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $4.66.

How much money does CorMedix make?

CorMedix has a market capitalization of $177.48 million and generates $240,000.00 in revenue each year. The biotechnology company earns $-22,030,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does CorMedix have?

CorMedix employs 35 workers across the globe.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

Where are CorMedix's headquarters?

CorMedix is headquartered at 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at (908) 517-9500.